Observed tamoxifen drug interactions are dependent on bot...

연구 요약

Observed tamoxifen drug interactions are dependent on both CYP2D6 phenotype and inhibitor potency.

The Journal of pharmacy and pharmacology 학술지에 발표된 이 연구는 Keller DN, Medwid SJ, Legan RM 외 연구팀이 수행하였습니다.

핵심 내용

OBJECTIVES: Tamoxifen is a prodrug that undergoes cytochrome P450(CYP)-mediated bioactivation to its active metabolite endoxifen, primarily due to CYP2D6. We aimed to investigate the clinical impact of CYP2D6 phenotype on the conversion of tamoxifen to endoxifen as well as the interplay of genetic variation and drug interactions. METHODS: Samples were analyzed from a cohort of 932 breast cancer patients on tamoxifen therapy. CYP2D6 phenotype, tamoxifen, endoxifen, 4-hydroxytamoxifen, and N-desmethyl tamoxifen plasma concentrations and antidepressant CYP2D6 inhibitor use were analyzed. KEY FINDINGS: There was a significant effect of CYP2D6 phenotype and CYP2D6 inhibitor use on endoxifen concentrations (pinteraction < 0.05). CYP2D6 inhibition was predictive of patients who attained plasma endoxifen concentrations below the 16 nM and 9 nM threshold. CYP2D6 poor metabolizers and CYP2D6 normal or intermediate metabolizers on strong CYP2D6 inhibitors had the largest proportion of patients below an endoxifen threshold of 16 or 9 nM. CONCLUSIONS: Patients on tamoxifen should avoid strong CYP2D6 inhibitors as their endoxifen concentrations are similar to CYP2D6 poor metabolizers. The utility of endoxifen concentrations and which threshold to consider in clinical practice remains unclear. Ultimately, the clinical impact of mild or moderate CYP2D6 inhibitors on CYP2D6 normal or intermediate metabolizer depends on the endoxifen threshold applied.

일반인을 위한 해석

이 연구는 약물 또는 영양제의 안전한 사용에 관한 과학적 근거를 제공할 수 있습니다. 다만, 개별 연구 결과만으로 일반화하기는 어려우며, 추가적인 연구가 필요할 수 있습니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41660717)